Novo Nordisk: positive opinion from the European Medicines Agency

(CercleFinance.com) - Novo Nordisk has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the approval of Alhemo ® (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older with inhibitor-positive hemophilia A or B.


Hemophilia is a rare coagulation disorder that impairs the body's ability to produce blood clots, a process necessary to stop bleeding.

Currently, it is estimated that up to 30% of people with severe hemophilia A develop inhibitors, and 5-10% of people with severe hemophilia B develop inhibitors.

' If approved, Alhemo® would be an important addition to our growing portfolio of hemophilia medicines, as it offers the potential of daily prophylaxis to prevent bleeding in people with hemophilia who have developed the complication of inhibitors' said Stephanie Seremetis, Chief Medical Officer of the Hemophilia Department at Novo Nordisk.

Copyright (c) 2024 CercleFinance.com. All rights reserved.